Objectives
There is an acute problem concerning lymphoma treatment in Ukraine. Previously, due to unavailability of up-to-date chemotherapy (CT) regimes, only 20% of lymphoma patients had a chance for persistent remission after the treatment, 40-60% of patients had response to treatment and only 35% of patients had 5-year survival rates. Todays clinical protocols of therapy in lymphoma patients take into account world's experience. 
Methods

Results
Clinical protocols in lymphoma patients with taking into account the obtained data have been developed. They included medical technologies with proven efficacy. However, it should be noted that some of the CT schemes with sufficient efficacy in clinical trials in patients with recurrent and refractory forms of lymphoma, high grade of aggressive non-Hodgkin lymphoma include bortezomib, vinorelbine, gemcitabine, carboplatin, cisplatin. These agents are not licensed for lymphoma, that results in impossibility to prescribe such regimes to patients.
Conclusions
The up-to-date CT regimes allow achieving better results. However, the treatment is expensive, but prolongs survival and improves quality of life. Thus, introduction of modern approaches to the treatment of lymphomas in Ukraine and harmonization of Ukrainian and world's practices will provide comprehensive and effective medical care for patients. Alternating regimen CR relapse-free survivals at 2 years -85%, overall disease-free survivals at 2 years -57%, overall survivals at 2 years -88% Hybrid regimen CR relapse-free survivals at 2 years -79%, overall disease-free survivals at 2 years -32%, overall survivals at 2 years -88% Randomized study, median follow-up time of 8.1 years.
Additional information
Radiation after CT or no further treatment.
Remission duration, relapse-free survival, and overall survival were similar for the two groups. 5-year remission. 169 patients with nodular sclerosis: 82% for the low-dose radiation group and 60% for the no further treatment group. For all patients with bulky disease: 75% for the low-dose radiation group and 57% for the no further treatment group.
No difference in overall survival was noted between low-dose radiation and no further treatment in all patients or major subgroups.
The 5-year survival was 86% for all patients who had a complete response as well as for patients in the nodular sclerosis subgroup. 
